Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)

References

• Remstein, E.D., Hanson, C.A., Kyle, R.A., Hodnefield, J.M. and Kurtin, P.J. (2003) "Despite apparent morphologic and immuno-phenotypic heterogeneity, Waldenström's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells", Semin. °flea, 30, 182–186.
   Google Scholar
• Johnson, S.A., Oscier, D.G. and Leblond, V. (2002) "Walden-ström's macroglobulinaemia", Blood Rev., 16, 175–184.
   PubMed Web of Science ®Google Scholar
• Thalhammer-Scherrer, R., Geissler, K., Schwarzinger, I., et al. (2000) "Fludarabine therapy in Waldenström's macroglobuline-mia", Ann. Hematol., 79, 556–559.
   Web of Science ®Google Scholar
• Kyle, R.A., Greipp, P.R., Gertz, M.A., et al. (2000) "Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil", Br. J. Haematol., 108, 737–742.
   Web of Science ®Google Scholar
• Bosly, A., Keating, M.J., Stasi, R. and Bradstock, K. (2002) "Rituximab in B-cell disorders other than non-Hodgkin's lympho-ma", Anticancer Drugs, 13\(Suppl 2), S25—S33.
   PubMed Web of Science ®Google Scholar
• San Miguel, J.F., Vidriales, M.B., Ocio, E., et al. (2003) "Immunophenotypic analysis of Waldenström's macroglobuline-mia", Semin. Oncol., 30, 187-195. Erratum: Semin. Oncol., 15, 427.
   Google Scholar
• Weber, D.M., Dimopoulos, M.A., Delasalle, K., Rankin, K., Gavino, M. and Alexanian, R. (2003) "2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia", Semin. °flea, 30, 243–247.
   Google Scholar
• Mori, A., Tamaru, J. and Kondo, H. (2002) "Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14", Eur. J. Haematol., 69, 321 — 323.
   PubMed Web of Science ®Google Scholar
• Treon, S.P. and Anderson, K.C. (2000) "The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders", Semin. °flea, 27(Suppl 12), 79–85.
   Google Scholar
• Weber, D., Treon, S.P., Emmanouilides, C., et al. (2003) "Uniform response criteria in Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia", Semin. °flea, 30, 127 — 131.
   Google Scholar
• Kaplan, E.L. and Meier, P. (1958) "Nonparametric estimation from incomplete observations", J. Am. Stat. Assoc., 53, 457 —481.
   Web of Science ®Google Scholar
• Peto, R. and Peto, J. (1972) "Asymptotically efficient rank invariant test procedures", J. R. Stat. Soc. A, 135, 185–207.
   Web of Science ®Google Scholar
• Treon, S.P., Kelliher, A., Keele, B., et al. (2003) "Expression of serotherapy target antigens in Waldenström's macroglobulinemia: therapeutic applications and considerations", Semin. ()flea, 30, 248–252.
   Google Scholar
• Byrd, J.C., White, C.A., Link, B., et al. (1999) "Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity", Ann. °flea, 10, 1525–1527.
   Google Scholar
• Weide, R., Heymanns, J. and Koppler, H. (1999) "Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia", Leuk. Lymphoma, 36, 203–206.
   PubMed Web of Science ®Google Scholar
• Weide, R., Heymanns, J. and Koppler, H. (2000) "The polyneuro-pathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 mono-clonal antibody rituximab", Br. J. Haematol., 109, 838–841.
   Web of Science ®Google Scholar
• Treon, S.P., Shima, Y., Grossbard, M.L., et al. (2000) "Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens", Ann. Oncol.,11(Suppl 1), 5107 — 5111.
   Google Scholar
• Treon, S.P., Agus, D.B., Link, B., et al. (2001) "CD20-directed antibody-mediated immunotherapy induces responses and facil-itates hematologic recovery in patients with Waldenström's macro-globulinemia", J. Immunother., 24, 272–279.
   Web of Science ®Google Scholar
• Dimopoulos, M.A., Zervas, C., Zomas, A., et al. (2002) "Treatment of Waldenström's macroglobulinemia with rituximab", J. Clin. Oncol., 20, 2327–2333.
   Web of Science ®Google Scholar
• Dimopoulos, M.A., Zervas, C., Zomas, A., et al. (2002) "Extended rituximab therapy for previously untreated patients with Walden-ström's macroglobulinemia", Clin. Lymphoma, 3, 163–166.
   Web of Science ®Google Scholar
• Dhodapkar, M.V., Jacobson, J.L., Gertz, M.A., Crowley, J.J. and Barlogie, B. (2003) "Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: an update of a US intergroup trial (SWOG S9003)", Semin. °flea, 30, 220–225.
   Google Scholar
• Mohammad, R.M., Aboukameel, A., Nabha, S., Ibrahim, D. and Al-Katib, A. (2002) "Rituximab, cyclophosphamide, dexametha-sone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenström's macroglobulinemia patient", J. Drug Target, 10, 405–410.
   PubMed Web of Science ®Google Scholar
• Kanelli, S., Ansell, S.M., Habermann, T.M., Inwards, D.J., Tuinstra, N. and Witzig, T.E. (2001) "Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis", Leuk. Lymphoma, 42, 1329–1337.
   PubMed Web of Science ®Google Scholar
• Gertz, M.A., Anagnostopoulos, A., Anderson, K., et al. (2003) "Treatment recommendations in Waldenström's macroglobuline-mia: consensus panel recommendations from the Second Interna-tional Workshop on Waldenström's Macroglobulinemia", Semin. Oncol., 30, 121–126.
   Google Scholar
• Emmanouilides, C. (2003) "Radioimmunotherapy for Walden-ström's macroglobulinemia", Semin. Oncol., 30, 258–261.
   Google Scholar
• Vose, J.M. (2000) "Therapeutic uses of MAbs directed against CD20", Cytotherapy, 2, 455 —461.
   Google Scholar